华熙生物科技股份有限公司 2024年年度股东大会会议资料 证券代码：688363 证券简称：华熙生物 2024 年年度股东大会会议资料 2025 年 6 月 华熙生物科技股份有限公司 2024年年度股东大会会议资料 2024 年年度股东大会会议资料目录 | 华熙生物科技股份有限公司 年年度股东大会会议须知 2024 | | | 2 | | --- | --- | --- | --- | | 华熙生物科技股份有限公司 | 年年度股东大会会议议程 2024 | | 4 | | 议案一 | 关于审议公司 年年度报告及其摘要的议案 2024 | | 6 | | 议案二 | 关于审议 年度董事会工作报告的议案 2024 | | 7 | | 议案三 | 关于审议 年度监事会工作报告的议案 2024 | | 18 | | 议案四 | 关于 2025 年度公司董事、监事薪酬方案的议案 | | 23 | | 议案五 | 关于公司 2024 年度财务决算报告的议案 | | 24 | | 议案六 | 关于公司 2024 年度利润分配预案的议案 | | 33 | | 议案七 | 关于取消监事会、修订《公司章程》并办理工商变更登记的议 ...

Core Viewpoint - The leading domestic hyaluronic acid company, Huaxi Biological, has publicly criticized 10 research reports from 9 securities firms for containing misleading statements, highlighting the competitive dynamics between hyaluronic acid and recombinant collagen products [1][2][3] Group 1: Criticism of Research Reports - Huaxi Biological published a nearly 5000-word article accusing the reports of creating inflated expectations around recombinant collagen products at the expense of the hyaluronic acid industry [2][3] - The criticized reports include those from major firms such as Huatai Securities, Ping An Securities, and Western Securities, with specific claims of bias and contradictions in their analyses [3][5][12] - Some reports have been reportedly deleted, particularly the one from Western Securities, raising questions about the integrity of the research [5][22] Group 2: Market Dynamics and Product Comparison - The reports discussed the advantages and disadvantages of hyaluronic acid and recombinant collagen, with some showing a preference for collagen, which has led to concerns about the objectivity of the analyses [7][16] - Huaxi Biological's core product is hyaluronic acid, while the competitor, Juzhi Biological, focuses on recombinant collagen, both of which are used in medical and cosmetic applications [3][19] - The market for recombinant collagen is expected to grow rapidly, potentially surpassing that of hyaluronic acid, due to its higher technical barriers and product characteristics [20][19] Group 3: Analyst Reactions and Industry Implications - The incident has sparked discussions among analysts, with some suggesting that securities firms may feel pressured to remain silent due to their weaker position against prominent companies like Huaxi Biological [23][22] - Analysts have noted that while both products have their merits, the technical complexity of recombinant collagen is higher than that of hyaluronic acid, reflecting broader trends in consumer preferences [23][20] - Despite the criticism, several securities firms continue to issue positive ratings for Huaxi Biological, indicating a complex relationship between market perception and research integrity [22][19]

丨证券研究报告丨 公司研究丨点评报告丨华熙生物（688363.SH） [Table_Title] 华熙生物 2024 年报及 2025 一季报点评：医疗 终端增势亮眼，护肤品业务持续调整 报告要点 [Table_Summary] 2024 年，公司实现营业收入 53.7 亿元，同比下滑 11.6%；实现归母净利润 1.7 亿元，同比下 滑 70.6%。2024Q4，公司实现营业收入 15.0 亿元，同比下滑 19.3%；实现归母净利润-1.9 亿 元，扣非归母净利润-2.2 亿元。2025Q1，公司实现营业收入 10.8 亿元，同比下滑 20.8%；实 现归母净利润 1.0 亿元，同比下滑 58.1%。 分析师及联系人 [Table_Author] SAC：S0490514080004 SAC：S0490520080019 SFC：BUV258 李锦 罗祎 曾维朵 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 华熙生物（688363.SH） cjzqdt11111 [Table_Title 华熙生物 2024 2] 年报及 2025 一季报点评：医疗 终端增势 ...

作 者丨孙永乐 编 辑丨巫燕玲 图 源丨图虫 近日，昔日"医美茅"、A股医美龙头华熙生物（6 8 8 3 6 3 .SH）在官方微信公众号发文驳斥透明 质酸（即"玻尿酸"）"过时论"，并公开点名9家券商研报，称其言论严重误导市场，引发行业 广泛关注。 据华熙生物最新透露，其在发声前已获两大行业协会支持，并已于上周向证监会反映 文章提及的内容。目前已有券商删除涉事研报，甚至有部分机构向上市公司致歉。 截至5月2 3日，2 1世纪经济报道记者通过Wi n d、同花顺iFi nD检索发现，上述提及的9家券商 发布的1 0篇行业研报， 有3篇已未能在平台上检索到，其余7篇尚能查看 。 根 据 记 者 检 索 ， 删 除 的 研 报 或 为 平 安 证 券 《 新 消 费 研 究 之 胶 原 蛋 白 行 业 ： 巨 子 生 物 （H0 1 8 0 0 .HK）》、 西部证券 《科技为舟，引领胶原蛋白健康美学》、 华福证券 《巨子生 物（2 3 6 7 .HK）重组胶原蛋白领军者，紧握行业发展机遇》。 截至记者发稿时止，至少包括 信达证券、华泰证券、方正证券、安信证券、申港证券、国金 证券尚未对相关研报做出处置 。 与其 ...

Core Viewpoint - The article discusses the controversy surrounding Huaxi Biological's rebuttal of the claims made by nine brokerage firms regarding hyaluronic acid being "outdated" and the promotion of recombinant collagen as a superior alternative, highlighting the impact of these claims on the market and the industry [2][4][9]. Group 1: Company Actions - Huaxi Biological publicly refuted the claims about hyaluronic acid and named nine brokerage firms for misleading reports, which has led to some brokerages retracting their reports and issuing apologies [2][8]. - The company received support from two industry associations before making its statement and has reported the matter to the China Securities Regulatory Commission [2][8]. - As of May 23, three of the ten reports mentioned have been removed from public access, while the remaining seven are still available for viewing [8][9]. Group 2: Industry Context - The medical beauty industry is characterized by a high overlap between capital market participants and enterprise users, making capital evaluations significantly impactful on the competitive landscape, which explains Huaxi Biological's strong response [2][4]. - The article emphasizes that the claims made in the brokerage reports lack scientific basis and are driven by speculative capital, which could harm a key industry in China [6][9][24]. Group 3: Scientific Claims - Huaxi Biological argues that the reports promoting recombinant collagen over hyaluronic acid are misleading and lack substantial scientific evidence, asserting that both substances have their unique benefits and should not be directly compared [23][24]. - The company highlights that the regulatory approvals for hyaluronic acid products far exceed those for recombinant collagen, indicating a stronger safety profile for hyaluronic acid [25][26]. Group 4: Regulatory Environment - The article notes that the regulatory environment for brokerage reports is tightening, with recent inspections revealing issues in compliance and the need for better management of report quality and information sources [18][20]. - There is a growing concern about the potential for misleading information in brokerage reports, which could lead to regulatory actions against the firms involved if found to be in violation of established guidelines [21][22].

Core Viewpoint - The company is advancing its product offerings in the field of ergothioneine, with significant developments in both raw materials and functional skincare products [1] Group 1: Product Development - The company’s food-grade ergothioneine is set to receive Self-GRAS certification in the U.S. by 2024 [1] - The company has launched Bioyouth™-EGT Pro and Bioyouth™-EGT Pure, with full production capacity at a tonnage level, and raw material sales have exceeded one million [1] Group 2: Industry Standards - The company has led the drafting of the group standard for high-purity ergothioneine in cosmetics, which was officially implemented in September 2023 [1] Group 3: Nutritional Science Innovation - The company focuses on four core areas and has developed a product matrix around key raw materials such as hyaluronic acid, ergothioneine, rhodiola rosea glycosides, and GABA [1] - Oral ergothioneine products are now available on Tmall through the company’s flagship store, utilizing cross-border e-commerce for sales [1]

券商研报被上市公司"点名"风波延续。5月21日晚，近期处于市场关注焦点的华熙生物再发一文，就5月17日的发文内容做进一步解释，并再度提及 券商研报。回顾此前，华熙生物一次性点名华泰证券、西部证券、国金证券等多家券商研报，并直指其中存在误导性"结论"。有业内人士表示，上 市公司对券商研报的质疑，关键意义在于重新定义上市公司与券商投研的互动关系，从这一角度看，或存在积极意义。对券商研究所而言，未来需 要不断提升专业水平，尽量减少被质疑的可能性。论据专业性、逻辑严谨性是未来研报的核心。 华熙生物再发文 近期，备受市场关注的华熙生物在5月21日再度发文，就此前5月17日的发文内容做进一步解释，也再度提及券商研报内容。 在华熙生物看来，部分券商研报所涉及的企业在医美填充领域并没有获得任何三类医疗器械注册证，所以并不具备对医美填充成分技术的评估和宣 传条件。券商研报中这种B优于A的结论，是缺乏任何公开数据或国内外科研论文结论支持的。 回顾5月17日，华熙生物曾在其官方微信号发文指出，2022年开始，随着资本市场不断追求新的公司题材，重组胶原蛋白概念被看似幸运地选中 了。为了营造比透明质酸产业更大的预期，围绕某重组胶原企业 ...

Core Viewpoint - The recent discussions surrounding hyaluronic acid and recombinant collagen in the medical beauty industry have intensified, particularly following Huaxi Biological's publications defending hyaluronic acid's relevance and efficacy over recombinant collagen [1][4][5]. Group 1: Company Response and Market Dynamics - Huaxi Biological has issued statements refuting claims that hyaluronic acid is outdated, emphasizing the importance of both hyaluronic acid and collagen in skin health, and their interdependent roles in extracellular matrix (ECM) function [4][5]. - The company highlighted that it holds the highest number of approved Class III medical device certifications for hyaluronic acid products, asserting that there is no evidence to suggest that recombinant collagen is safer than hyaluronic acid [5]. - The shift in market focus from hyaluronic acid to recombinant collagen has led to a decline in the stock prices and performance of traditional hyaluronic acid companies, while recombinant collagen firms have seen significant gains [6]. Group 2: Financial Performance - Huaxi Biological reported a revenue decline of 11.61% year-on-year, with total revenue of approximately 5.371 billion yuan and a net profit drop of 70.59%, amounting to about 174 million yuan for 2024 [6][7]. - The company’s medical beauty segment showed positive growth, with raw material business revenue increasing by 9.47% to 1.236 billion yuan, while the medical terminal business grew by 32.03% to 1.44 billion yuan [7]. - The significant decline in overall performance was attributed to challenges in the consumer goods segment, which faced intensified competition and strategic adjustments, resulting in a 31.62% revenue drop to 2.569 billion yuan [7]. Group 3: Management Changes and Corporate Governance - In response to internal issues, Huaxi Biological has initiated a major management reform, focusing on addressing corruption and improving corporate governance, with a strict deadline for employees to report any misconduct [9][10]. - The company has undergone significant personnel changes, including the retirement of senior executives and the appointment of new management to align with strategic development needs [10]. - The management reform aims to correct previous lax practices and establish a more robust operational framework for long-term growth [9].

Core Viewpoint - Huaxi Biological criticized ten research reports from nine brokerages, claiming they misled the market by promoting a "hyaluronic acid obsolescence theory" in favor of recombinant collagen products [2][3][5] Group 1: Research Reports Criticism - Huaxi Biological specifically named four reports from brokerages including Huatai Securities and Anxin Securities, which emphasized the advantages of recombinant collagen over hyaluronic acid in terms of efficacy and safety [3][5] - The reports in question did not explicitly use the term "obsolete" but suggested that collagen had superior applications in certain scenarios [5] - Huaxi Biological's article indicated that the emergence of the "hyaluronic acid obsolescence" narrative was driven by "restless capital" seeking new investment themes [3][9] Group 2: Timeline and Context - The criticism of the research reports is rooted in a timeline starting from 2022, when the recombinant collagen concept gained traction in the capital market [7][10] - Huaxi Biological itself entered the recombinant collagen market in April 2022 by acquiring a 51% stake in Beijing Yierkang Biological Engineering for 233 million yuan [9] - The reports were published between 2022 and 2024, with the earliest being from August 2022 and the latest from February 2024 [8] Group 3: Regulatory and Compliance Issues - The article raised questions about the compliance and independence of the research reports, referencing the "Interim Regulations on the Release of Securities Research Reports" which mandates objectivity and fairness [10][11] - There were indications that some brokerages had deleted the criticized reports from the WIND platform, although they remained accessible on other platforms like Choice [5][11] - The production process of research reports involves ensuring data legality and undergoing compliance checks before publication, highlighting the importance of rigorous standards in the industry [11]

沪指5月22日下跌0.22%，申万所属行业中，今日上涨的有3个，涨幅居前的行业为银行、传媒、家用电 器，涨幅分别为1.00%、0.12%、0.04%。跌幅居前的行业为美容护理、社会服务，跌幅分别为2.03%、 1.80%。美容护理行业位居今日跌幅榜首位。 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002094 | 青岛金王 | 6.60 | 38.89 | 49250.10 | | 600249 | 两面针 | 4.83 | 22.21 | 16705.65 | | 001328 | 登康口腔 | 2.73 | 14.01 | 2803.29 | | 688363 | 华熙生物 | -1.01 | 1.08 | 1449.76 | | 002511 | 中顺洁柔 | -0.14 | 1.34 | 1289.38 | | 300886 | 华业香料 | -5.41 | 21.25 | 262.17 | | 300955 | 嘉亨家化 | 3.58 | 24.50 | 122.21 | | 30 ...